RetaCalc
Protocol library
SingleApprovedRegulatory LabelSourced

Semaglutide

A GLP-1 receptor agonist used in several authorised medicines. Formulation, indication and route are product-specific and must not be treated as interchangeable.

Evidence context, not a personal protocol

Quantities below reproduce study or label context. They do not assess suitability, product equivalence or individual risk.

Regimens studied

Adults meeting the authorised Wegovy indication

The label uses once-weekly administration with staged escalation before the maintenance period

Consult the current medicine label for the exact schedule and missed-dose rules; this summary is not a personal regimen.

View source

Evidence summary

Semaglutide has a large clinical evidence base, but the evidence is tied to specific regulated formulations and participant populations.

Formulation matters

Do not infer equivalence between an authorised pen or tablet and a research vial. Concentration calculations cannot establish identity, purity, sterility or bioequivalence.

Warnings and contraindications

Different semaglutide products have different indications, formulations and instructions.
Authorised labels contain serious warnings and contraindications requiring clinical assessment.

Contraindications reported by the source

Personal or family history of medullary thyroid carcinoma for relevant US products
Multiple Endocrine Neoplasia syndrome type 2 for relevant US products